Huaren Pharmaceutical Co Ltd

Huaren Pharmaceutical has a market capitalization of CNY 3.48 billion and a price-to-book ratio of 4.15, indicating that the market values the company at a premium to its book value. The company's liquidity position is characterized as medium risk, with a current ratio of 0.67, suggesting that it may struggle to meet short-term obligations with its current assets. The company's free cash flow is negative at CNY -442.36 million, which indicates that it is spending more on capital expenditures than it is generating in operating cash flow. In terms of profitability, Huaren Pharmaceutical is underperforming, with a net loss of CNY -462.90 million and an operating loss of CNY -455.98 million. The company's return on equity is -55.25%, and its return on assets is -17.13%, both of which are significantly below the industry median for pharmaceutical companies. The gross profit margin is 34.6%, which is in line with the industry average, but the operating margin is -34.5%, indicating that the company is not able to convert its gross profit into operating profit. The company's revenue is concentrated in its domestic market, with no significant international operations disclosed. The company's long-term debt is CNY 1.24 billion, and its debt-to-equity ratio is 1.48, which is higher than the industry median, indicating a higher financial leverage. The company's total liabilities exceed its total assets, with a debt burden that could pose a risk to its financial stability. Looking at the growth trajectory, the company's recent financial performance shows a decline in profitability, with a net loss and an operating loss. The company's revenue for the period is CNY 1.32 billion, but there is no indication of growth in the most recent period. The company's capital expenditures are CNY -48.98 million, which is a small portion of its operating cash flow, suggesting that the company is not heavily investing in new projects or expansion. The risk assessment for Huaren Pharmaceutical indicates a medium liquidity risk and a low dilution risk. The company's key financial flag is that its net cash is negative after subtracting total debt, which could limit its ability to fund operations or invest in growth opportunities. The company's dilution potential is low, with no significant changes in shares outstanding between basic and diluted shares. The company has not made any adjustments to its valuations, suggesting that the market price is in line with its fundamentals. Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company's 10-K filing does not mention any material risks or events that could impact its financial performance in the near term. The company's recent earnings call transcripts do not provide any additional insights into its strategic direction or operational performance.